Key Takeaways
- Angitia Biopharmaceuticals has shifted focus from its lead asset AGA111 to two earlier-stage drug candidates.
- The company is now concentrating on AGA2118 and AGA2115, targeting osteoporosis and osteogenesis imperfecta.
- Angitia aims to compete with Amgen’s Evenity by addressing regulatory pathways crucial for bone growth.
Strategic Shift at Angitia Biopharmaceuticals
Angitia Biopharmaceuticals, which recently raised $130 million, is pivoting away from its lead drug AGA111, a recombinant human BMP-6 protein intended to promote bone growth. This decision follows the termination of a Phase 3 study for AGA111 in patients undergoing spinal fusion surgery. Notably, Angitia clarified that this termination was not linked to safety issues as per the federal clinical trials database.
The confirmation of this change was reported by a source familiar with the company’s strategic decisions. Angitia is now channeling its efforts towards two of its bispecific antibodies: AGA2118 and AGA2115. These candidates are in Phase 2 trials, focusing on osteoporosis and osteogenesis imperfecta, respectively.
Both AGA2118 and AGA2115 target sclerostin and DKK1, proteins that inhibit the Wnt signaling pathway, essential for bone health. By inhibiting these targets, Angitia aims to stimulate bone tissue growth. This approach places Angitia in direct competition with Amgen’s Evenity, which is designed to treat osteoporosis in postmenopausal women who face a high risk of fractures. Angitia’s strategy intends to capitalize on the growing interest in therapeutic options addressing bone-related conditions.
The leadership of Angitia, particularly CEO Hua Zhu (David) Ke, M.D., is noteworthy. Dr. Ke played a significant role in the development of Evenity during his eight years at Amgen and has a rich industry background that includes a 13-year tenure at Pfizer. His experience could prove invaluable as Angitia refocuses its developmental pipeline.
Headquartered in Guangzhou, China, with an additional base in Westlake Village, California, Angitia has successfully attracted substantial investment from prominent venture capital firms, including Bain Capital, RA Capital Management, Frazier Life Sciences, and Venrock Healthcare Capital Partners.
This transition underscores a strategic recalibration within Angitia, aiming for innovative solutions in the ever-evolving biopharmaceutical landscape focused on musculoskeletal health. The company is well-positioned to make significant strides in addressing critical bone health issues with its new product candidates, which may hold promise for future clinical success.
The content above is a summary. For more details, see the source article.